{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T01:30:27Z","timestamp":1755999027384,"version":"3.41.0"},"reference-count":139,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","seminarsinnephrology.org","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.semnephrol.2018.05.007","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T19:46:46Z","timestamp":1533325606000},"page":"369-382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease"],"prefix":"10.1016","volume":"38","author":[{"given":"Elani","family":"Streja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan A.","family":"Streja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Soohoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carola-Ellen","family":"Kleine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jui-Ting","family":"Hsiung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2018.05.007_bib0001","unstructured":"What is precision medicine? Available from: https:\/\/ghr.nlm.nih.gov\/primer\/precisionmedicine\/definition."},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0002","article-title":"HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis","volume":"5","author":"Palmer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0003","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/eurheartj\/eht065","article-title":"Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"34","author":"Hou","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0004","doi-asserted-by":"crossref","first-page":"732","DOI":"10.2215\/CJN.07460714","article-title":"Statins and cardiovascular primary prevention in CKD: a meta-analysis","volume":"10","author":"Major","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2261-14-19","article-title":"Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials","volume":"14","author":"Zhang","year":"2014","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0006","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl."},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0007","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2014.31","article-title":"Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient","volume":"85","author":"Wanner","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0008","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/M13-2453","article-title":"Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline","volume":"160","author":"Tonelli","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0009","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0010","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0011","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1681\/ASN.2016090957","article-title":"Benefit of ezetimibe added to simvastatin in reduced kidney function","volume":"28","author":"Stanifer","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0012","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"Lloyd-Jones","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0013","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jacc.2007.11.072","article-title":"Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study","volume":"51","author":"Shepherd","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0014","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0015","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0016","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jacc.2010.01.020","article-title":"Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein","volume":"55","author":"Ridker","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006886","article-title":"High-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"5","author":"Yan","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0018","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/2047487314525531","article-title":"What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice","volume":"21","author":"Finegold","year":"2014","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0019","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.8215.1","article-title":"Statin non-adherence: clinical consequences and proposed solutions","volume":"5","author":"Rosenson","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0020","doi-asserted-by":"crossref","first-page":"685","DOI":"10.18553\/jmcp.2016.22.6.685","article-title":"Patterns of statin use in a real-world population of patients at high cardiovascular risk","volume":"22","author":"Lin","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0021","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.288.4.462","article-title":"Adherence with statin therapy in elderly patients with and without acute coronary syndromes","volume":"288","author":"Jackevicius","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0022","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1517\/14740338.2015.1039980","article-title":"Statin intolerance \u2013 an attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"14","author":"Banach","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0023","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.amjcard.2014.02.033","article-title":"Statin intolerance","volume":"113","author":"Ahmad","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0024","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ahj.2016.01.016","article-title":"Protocol for analyses of adverse event data from randomized controlled trials of statin therapy","volume":"176","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0025","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/tpj.2013.27","article-title":"Providing patients with pharmacogenetic test results affects adherence to statin therapy: results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial","volume":"14","author":"Charland","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0026","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jpainsymman.2005.05.013","article-title":"The impact of chronic pain on depression, sleep, and the desire to withdraw from dialysis in hemodialysis patients","volume":"30","author":"Davison","year":"2005","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0027","first-page":"111","article-title":"Pain management in patients with chronic kidney disease","volume":"2","author":"Pham","year":"2009","journal-title":"NDT Plus"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0028","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.nefro.2016.03.024","article-title":"Musculoskeletal pain in patients with chronic kidney disease","volume":"36","author":"Caravaca","year":"2016","journal-title":"Nefrologia"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0029","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2369-15-6","article-title":"Factors associated with chronic musculoskeletal pain in patients with chronic kidney disease","volume":"15","author":"Hsu","year":"2014","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0030","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11883-016-0573-6","article-title":"Pharmacogenetics of lipid-lowering agents: precision or indecision medicine?","volume":"18","author":"Alfonsi","year":"2016","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0031","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/pr.110.002857","article-title":"Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake","volume":"63","author":"Niemi","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0032","doi-asserted-by":"crossref","first-page":"35669","DOI":"10.1074\/jbc.M103792200","article-title":"Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans","volume":"276","author":"Tirona","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0033","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/bcp.13207","article-title":"Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1)","volume":"83","author":"Lee","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0034","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/clpt.2012.221","article-title":"Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism","volume":"94","author":"Tomita","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0035","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2013a genomewide study","volume":"359","author":"Search Collaborative Group","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0036","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/FPC.0b013e328343dd7d","article-title":"Cerivastatin, genetic variants, and the risk of rhabdomyolysis","volume":"21","author":"Marciante","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0037","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJM200202143460721","article-title":"Cerivastatin and reports of fatal rhabdomyolysis","volume":"346","author":"Staffa","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0038","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/clpt.2010.255","article-title":"Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study","volume":"89","author":"Donnelly","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0039","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00228-014-1661-6","article-title":"Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2","volume":"70","author":"Ferrari","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0040","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/clpt.2013.161","article-title":"SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink","volume":"94","author":"Carr","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0041","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/tpj.2010.92","article-title":"Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin","volume":"12","author":"Brunham","year":"2012","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0042","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/FPC.0000000000000018","article-title":"The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study","volume":"24","author":"de Keyser","year":"2014","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0043","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","article-title":"The SLCO1B1*5 genetic variant is associated with statin-induced side effects","volume":"54","author":"Voora","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0044","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00228-017-2318-z","article-title":"SLCO1B1 521T >C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study","volume":"73","author":"Liu","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0045","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ahj.2013.01.025","article-title":"Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy","volume":"165","author":"Danik","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0046","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.atherosclerosis.2010.02.026","article-title":"Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study","volume":"211","author":"Puccetti","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0047","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00228-011-1125-1","article-title":"SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia","volume":"68","author":"Santos","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0048","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clpt.2005.06.013","article-title":"Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment","volume":"78","author":"Lee","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0049","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cca.2006.05.010","article-title":"Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males","volume":"373","author":"Zhang","year":"2006","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0050","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00228-014-1800-0","article-title":"Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States","volume":"71","author":"Birmingham","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0051","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00228-014-1801-z","article-title":"Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?","volume":"71","author":"Birmingham","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0052","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.xphs.2017.04.074","article-title":"Is ethnic variability in the exposure to rosuvastatin explained only by genetic polymorphisms in OATP1B1 and BCRP or should the contribution of intrinsic ethnic differences in OATP1B1 be considered?","volume":"106","author":"Sugiyama","year":"2017","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0053","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.xphs.2017.05.008","article-title":"Understanding the potential interethnic difference in rosuvastatin pharmacokinetics","volume":"106","author":"Benet","year":"2017","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0054","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0002-9149(96)00330-X","article-title":"Efficacy and tolerability of lovastatin in 459 African-Americans with hypercholesterolemia","volume":"78","author":"Prisant","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0055","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.amjmed.2008.08.033","article-title":"Relationship of ethnic origin, gender, and age to blood creatine kinase levels","volume":"122","author":"Neal","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0056","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ahj.2016.09.004","article-title":"On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)","volume":"182","author":"Blazing","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0057","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/1753944713513222","article-title":"Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients","volume":"7","author":"Suzuki","year":"2013","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0058","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/01.ATV.20.5.1340","article-title":"Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol","volume":"20","author":"Miettinen","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0059","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2215\/CJN.05170511","article-title":"Cholesterol synthesis, cholesterol absorption, and mortality in hemodialysis patients","volume":"7","author":"Rogacev","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0060","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/dmrr.697","article-title":"Markers of absorption and synthesis of cholesterol in men with type 1 diabetes","volume":"23","author":"Gylling","year":"2007","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0061","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1194\/jlr.M001487","article-title":"Baseline cholesterol absorption and the response to ezetimibe\/simvastatin therapy: a post-hoc analysis of the ENHANCE trial","volume":"51","author":"Jakulj","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0062","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Group","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0063","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000453626","article-title":"Effects of high density lipoprotein raising therapies on cardiovascular outcomes in patients with type 2 diabetes mellitus, with or without renal impairment: the Action to Control Cardiovascular Risk in Diabetes Study","volume":"45","author":"Papademetriou","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0064","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0065","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2337\/dc11-1109","article-title":"Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study","volume":"35","author":"Ting","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0066","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(00)04209-4","article-title":"Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study","volume":"357","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0067","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0068","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0069","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0070","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/ki.2014.383","article-title":"Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial","volume":"87","author":"Kalil","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0071","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11255-006-0001-x","article-title":"Extended release nicotinic acid \u2013 a novel oral agent for phosphate control","volume":"38","author":"Sampathkumar","year":"2006","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0072","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/j.ajkd.2014.11.033","article-title":"Niacin and the progression of chronic kidney disease","volume":"65","author":"Streja","year":"2015","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0073","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2147\/TCRM.S71559","article-title":"Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients","volume":"10","author":"Shin","year":"2014","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0074","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0075","unstructured":"Steg P. Evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab \u2013 ODYSSEY outcomes. Presented at: American College of Cardiology Annual Scientific Session; 2018 March 10; Orlando, FL. Available from: http:\/\/www.acc.org\/latest-in-cardiology\/clinical-trials\/2018\/03\/09\/08\/02\/odyssey-outcomes."},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0076","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0077","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.kint.2017.12.011","article-title":"Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease","volume":"93","author":"Toth","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0078","unstructured":"National Institutes of Health Clinical Center. Effect of PCSK9-antibody (Alirocumab) on dyslipidemia secondary to nephrotic syndrome. NCT03004001. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2016. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03004001. Updated March 13, 2017."},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0079","unstructured":"National Institutes of Health Clinical Center. Alirocumab in patients on a stable dialysis regimen. NCT03480568. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2018. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03480568. Updated April 9, 2018."},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0080","unstructured":"National Institutes of Health Clinical Center. Estimation study to assess the effect of severe renal impairment and end-stage renal disease hemodialysis on the pharmacokinetics of evolocumab. NCT02275156. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2016. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02275156. Updated January 29, 2016."},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0081","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1053\/j.ajkd.2013.10.042","article-title":"Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study","volume":"63","author":"Jin","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0082","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/ndt\/gft439","article-title":"Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome","volume":"29","author":"Liu","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0083","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169761","article-title":"Economic evaluation of PCSK9 inhibitors in reducing cardiovascular risk from health system and private payer perspectives","volume":"12","author":"Arrieta","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0084","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1161\/CIRCULATIONAHA.110.948562","article-title":"OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction","volume":"122","author":"Rauch","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0085","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMoa1003603","article-title":"n-3 fatty acids and cardiovascular events after myocardial infarction","volume":"363","author":"Kromhout","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0086","doi-asserted-by":"crossref","first-page":"c6273","DOI":"10.1136\/bmj.c6273","article-title":"Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial","volume":"341","author":"Galan","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0087","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1161\/STROKEAHA.107.509455","article-title":"Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial","volume":"39","author":"Tanaka","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0088","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/clc.22692","article-title":"Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial","volume":"40","author":"Bhatt","year":"2017","journal-title":"Clin Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.semnephrol.2018.05.007_bib0089","first-page":"FR","article-title":"Continuation of statin therapy initiated in pre-ESRD period and all-cause and cardiovascular mortality after transition to dialysis [abstract]","volume":"136","author":"Gosmanova","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0090","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.2215\/CJN.09121010","article-title":"Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis","volume":"6","author":"Marz","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0091","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.jacc.2015.03.551","article-title":"Intestinal cholesterol absorption, treatment with atorvastatin, and cardiovascular risk in hemodialysis patients","volume":"65","author":"Silbernagel","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"84","key":"10.1016\/j.semnephrol.2018.05.007_bib0092","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1046\/j.1523-1755.63.s84.3.x","article-title":"Dialysis modalities and dyslipidemia","author":"Attman","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0093","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1053\/j.ajkd.2007.07.023","article-title":"The association of lipid-modifying medications with mortality in patients on long-term peritoneal dialysis","volume":"50","author":"Goldfarb-Rumyantzev","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0094","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1093\/ndt\/gfr229","article-title":"Statin therapy is associated with improved survival in incident peritoneal dialysis patients: propensity-matched comparison","volume":"26","author":"Lee","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0095","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0096","article-title":"HMG CoA reductase inhibitors (statins) for kidney transplant recipients","volume":"1","author":"Palmer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0097","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2741\/4585","article-title":"Molecular mechanisms of disorders of lipid metabolism in chronic kidney disease","volume":"23","author":"Moradi","year":"2018","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0098","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/j.jrn.2013.01.022","article-title":"Role of HDL dysfunction in end-stage renal disease: a double-edged sword","volume":"23","author":"Moradi","year":"2013","journal-title":"J Ren Nutr"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0099","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.jacc.2012.09.013","article-title":"Dysfunctional high-density lipoprotein in patients on chronic hemodialysis","volume":"60","author":"Yamamoto","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0100","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/ki.2009.177","article-title":"In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide","volume":"76","author":"Vaziri","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0101","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.21037\/jtd.2017.10.155","article-title":"Serum high density lipoprotein cholesterol level and risk of death: let's avoid the extremes","volume":"9","author":"Moradi","year":"2017","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0102","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/ndt\/gfu022","article-title":"Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients","volume":"29","author":"Moradi","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0103","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.trsl.2008.11.007","article-title":"Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease","volume":"153","author":"Moradi","year":"2009","journal-title":"Transl Res"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0104","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1681\/ASN.2011070668","article-title":"Serum amyloid A in uremic HDL promotes inflammation","volume":"23","author":"Weichhart","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0105","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2215\/CJN.06560714","article-title":"Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis","volume":"10","author":"Kopecky","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0106","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10157-013-0857-x","article-title":"Chronic kidney disease induced dysfunction of high density lipoprotein","volume":"18","author":"Yamamoto","year":"2014","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0107","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1681\/ASN.2016030262","article-title":"HDL cholesterol efflux does not predict cardiovascular risk in hemodialysis patients","volume":"28","author":"Kopecky","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0108","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1681\/ASN.2014090857","article-title":"HDL cholesterol efflux predicts graft failure in renal transplant recipients","volume":"27","author":"Annema","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0109","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/ndt\/gfg074","article-title":"Oxidative stress in end-stage renal disease: an emerging threat to patient outcome","volume":"18","author":"Locatelli","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2796.2011.02397.x","article-title":"Myeloperoxidase is associated with incident coronary heart disease independently of traditional risk factors: results from the MONICA\/KORA Augsburg study","volume":"271","author":"Karakas","year":"2012","journal-title":"J Intern Med"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0111","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11883-012-0242-3","article-title":"Myeloperoxidase production by macrophage and risk of atherosclerosis","volume":"14","author":"Karakas","year":"2012","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0112","doi-asserted-by":"crossref","first-page":"30825","DOI":"10.1074\/jbc.M109.047605","article-title":"Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle","volume":"284","author":"Undurti","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0113","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1021\/tx9003775","article-title":"Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein","volume":"23","author":"Shao","year":"2010","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0114","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.0894-0959.2004.17605.x","article-title":"Linking oxidative stress and inflammation in kidney disease: which is the chicken and which is the egg?","volume":"17","author":"Himmelfarb","year":"2004","journal-title":"Semin Dial"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.ajkd.2006.03.047","article-title":"Serum myeloperoxidase and mortality in maintenance hemodialysis patients","volume":"48","author":"Kalantar-Zadeh","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0116","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1053\/j.ajkd.2010.05.008","article-title":"Prognostic value of plasma myeloperoxidase in ESRD patients","volume":"56","author":"Wang","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0117","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.numecd.2012.02.001","article-title":"Oxidised LDL\/LDL-cholesterol ratio and coronary artery calcification in haemodialysis patients","volume":"23","author":"Asamiya","year":"2013","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0118","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.atherosclerosis.2011.10.038","article-title":"Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients","volume":"220","author":"Honda","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0119","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.atherosclerosis.2014.05.948","article-title":"Niacin decreases leukocyte myeloperoxidase: mechanistic role of redox agents and Src\/p38MAP kinase","volume":"235","author":"Ganji","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0120","doi-asserted-by":"crossref","first-page":"e1182A","DOI":"10.1016\/S1567-5688(09)71149-3","article-title":"Niacin inhibits myeloperoxidase activity and oxidative degradation of HDL and apo AI in human leukocytic myeloid cell line HL-60: impact on anti-inflammatory properties of HDL","volume":"10","author":"Ganji","year":"2009","journal-title":"Atherosclerosis Suppl"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0121","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1161\/01.CIR.0000050628.11305.30","article-title":"The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial","volume":"107","author":"Tepel","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0122","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0140-6736(00)02783-5","article-title":"Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial","volume":"356","author":"Boaz","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0123","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/ki.2011.341","article-title":"Antioxidant therapy in hemodialysis patients: a systematic review","volume":"81","author":"Coombes","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0124","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw D","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0125","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1159\/000362906","article-title":"Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl","volume":"39","author":"Chin","year":"2014","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0126","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1373\/clinchem.2009.126029","article-title":"Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification?","volume":"55","author":"Schindhelm","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0127","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11306-016-1094-6","article-title":"Metabolomics enables precision medicine: \"a white paper, community perspective\"","volume":"12","author":"Beger","year":"2016","journal-title":"Metabolomics"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0128","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jacc.2015.12.060","article-title":"Metabolomic profiling of statin use and genetic inhibition of HMG-CoA reductase","volume":"67","author":"Wurtz","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0129","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/cpt.434","article-title":"Metabolomic and genome-wide association studies reveal potential endogenous biomarkers for OATP1B1","volume":"100","author":"Yee","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0130","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.clpt.2005.08.003","article-title":"The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment","volume":"78","author":"Fiegenbaum","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0131","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jacl.2011.01.001","article-title":"The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort","volume":"5","author":"Hoenig","year":"2011","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0132","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12944-015-0114-2","article-title":"ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysis","volume":"14","author":"Su","year":"2015","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0133","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/FPC.0b013e328012d0a9","article-title":"CYP2D6*4 polymorphism is associated with statin-induced muscle effects","volume":"17","author":"Frudakis","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0134","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1067\/mcp.2001.120251","article-title":"Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin","volume":"70","author":"Mulder","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0135","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/acr.21671","article-title":"Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0136","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.dmpk.2016.09.002","article-title":"A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients","volume":"31","author":"Sai","year":"2016","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0137","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-511X-6-7","article-title":"Genetic determinants of statin intolerance","volume":"6","author":"Oh","year":"2007","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0138","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.atherosclerosis.2011.07.007","article-title":"Mechanisms of statin-induced myalgia assessed by physiogenomic associations","volume":"218","author":"Ruano","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.semnephrol.2018.05.007_bib0139","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature12508","article-title":"A statin-dependent QTL for GATM expression is associated with statin-induced myopathy","volume":"502","author":"Mangravite","year":"2013","journal-title":"Nature"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027092951830069X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027092951830069X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T06:07:36Z","timestamp":1751782056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027092951830069X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":139,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S027092951830069X"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2018.05.007","relation":{},"ISSN":["0270-9295"],"issn-type":[{"type":"print","value":"0270-9295"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2018.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}